Forty percent of patients with diffuse large B-cell lymphoma had a complete response, most of which were durable UNIVERSITY OF CHICAGO MEDICAL CENTER In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory...